Use of Metformin and Survival in Patients with Hepatocellular Carcinoma (HCC) Undergoing Liver Directed Therapy: Analysis of a Nationwide Cancer Registry
- 22 May 2023
- journal article
- research article
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 46 (7) , 870-879
Abstract
Background Examine the association of metformin use and overall survival (OS) in patients with HCC undergoing image-guided liver-directed therapy (LDT): ablation, transarterial chemoembolization (TACE), or Yttrium-90 radioembolization (Y90 RE). Methods Using National Cancer Institute Surveillance, Epidemiology, and End Results registry and Medicare claims databases between 2007 and 2016, we identified patients ≥ 66 years who underwent LDT within 30 days of HCC diagnosis. Patients with liver transplant, surgical resection, and other malignancies were excluded. Metformin use was identified by at least two prescription claims within 6 months before LDT. OS was measured by time between first LDT and death or last Medicare observation. Comparisons were performed between both all and diabetic patients on and not on metformin. Results Of 2746 Medicare beneficiaries with HCC undergoing LDT, 1315 (47.9%) had diabetes or diabetes-related complications. Among all and diabetic patients, 433(15.8%) and 402 (30.6%) were on metformin respectively. Median OS was greater for patients on metformin (19.6 months, 95% CI 17.1–23.0) vs those not (16.0 months, 15.0–16.9; p = 0.0238). Patients on metformin had lower risk of death undergoing ablation (HR 0.70; 0.51–0.95; p = 0.0239) and TACE (HR 0.76, 0.66–0.87; p = 0.0001), but not Y90 RE (HR1.22, 0.89–1.69; p = 0.2231). Among diabetics, OS was greater for those on metformin vs those not (HR 0.77, 0.68–0.88; p < 0.0001). Diabetic patients on metformin had longer OS undergoing TACE (HR 0.71, 0.61–0.83; p < 0.0001), but not ablation (HR 0.74, 0.52–1.04; p = 0.0886) or Y90 RE (HR 1.26, 0.87–1.85; p = 0.2217). Conclusion Metformin use is associated with improved survival in HCC patients undergoing TACE and ablation.Keywords
This publication has 23 references indexed in Scilit:
- Metformin: A Novel Biological Modifier of Tumor Response to Radiation TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Survival Advantage Associated with Metformin Usage in Hepatocellular Carcinoma Patients Receiving Radiotherapy: A Propensity Score Matching Analysis2015
- Anti-Tumor Effects of Metformin in Animal Models of Hepatocellular Carcinoma: A Systematic Review and Meta-AnalysisPLOS ONE, 2015
- Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer RiskGastroenterology Research and Practice, 2015
- Emerging trends in hepatocellular carcinoma incidence and mortalityHepatology, 2014
- Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivoOncology Reports, 2013
- Metformin, a Diabetes Drug, Eliminates Tumor-Initiating Hepatocellular Carcinoma CellsPLOS ONE, 2013
- Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablationJournal of Gastroenterology and Hepatology, 2011
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNMAnnals of Surgical Oncology, 2010
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987